Reversal by heparin of norepinephrine-induced constriction of normal hand veins was studied. Venous size was measured using a linear variable differential transformer (LVDT) during infusions of saline, norepinephrine, insulin and norepinephrine, and graded doses of heparin with norepinephrine. Heparin reduced the venoconstrictive effects of norepinephrine (p Ͻ 0.01), with the effects beginning at 18.5 nmol/min (0.05 U/min) and reaching a maximum between 185 nmol/min and 1.85 mol/min (0.5 and 5 U/min). Maximal heparin-induced venorelaxation correlated with the maximal insulin effect within individuals (r = 0.8, p Ͻ 0.01) and was unchanged by the addition of insulin. Methylene blue, a non-specific inhibitor of the nitric oxide cGMP cascade, reduced heparin-induced venorelaxation. In conclusion, heparin in either physiologic or pharmacologic concentrations attenuated norepinephrine-induced venoconstriction. A common mechanism of venorelaxation by heparin and insulin is not excluded given the correlation and lack of additivity of maximum effects and their inhibition by methylene blue.
Introduction
Intravenous heparin has become standard therapy for patients with acute coronary syndromes. Clinical observations suggest that heparin provides more than its antithrombic effects for these patients. Some patients with unstable angina report immediate relief of chest pain when heparin is administered. Angina may recur soon after heparin infusion is stopped even though the partial thromboplastin time remains in the therapeutic range. Heparin may be acting as a vasodilator in those patients.
Heparin decreases blood pressure in spontaneously hypertensive rats [1] [2] [3] [4] and in humans during coronary artery bypass surgery. [5] [6] [7] It blocks norepinephrine-induced calcium currents in vitro. 8, 9 Heparin also has been shown to regulate and suppress endothelin-1 production in cultured endothelial cells 1,10,11 through a nitric oxide-dependent mechanism. 11 Endogenous heparin and heparin-like glucosaminoglycans have been detected in human plasma, [12] [13] [14] [15] and endothelial cells release heparin sulfates. 16 Endogenous heparin or heparin-like molecules may contribute to the overall regulation of vascular tone.
To test the hypothesis that heparin is vasoactive in humans, the effects of heparin on venous distension in cephalic or dorsal hand veins constricted with norepinephrine were studied. To begin to explore the mechanism of its effect, heparin was compared to and combined with insulin, a known endothelium-dependent vasodilator. [17] [18] [19] [20] [21] [22] To examine the role of guanylate cyclase, a final step in the nitric oxide-cGMP pathway, heparin was infused con-currently with methylene blue, a putative guanylate cyclase inhibitor.
Methods
Thirteen healthy, normotensive subjects, seven men and six premenopausal women, aged 25-40 years (mean 32), were recruited from the hospital community. All were non-smokers and had received no medications within the previous 14 days. Subjects were encouraged to have a light breakfast on the day of the experiment and to abstain from caffeine for at least 8 h prior to the start of the experiment. The protocol was approved by the Institutional Review Board of the Millard Fillmore Health System, and subjects gave written informed consent.
The subjects lay supine, covered with blankets. Because a drop in skin temperature below about 30°C would cause an abrupt increase in venoconstriction 23 it was opted to standardize to warm skin and relaxed veins; the subjects were required to feel almost too warm.
A 23-gauge needle was inserted in a region of a cephalic or dorsal hand vein without branches or tributaries. The arm then was elevated on an arm board at 30°from the horizontal to allow the veins to empty. Normal saline kept at room temperature was infused at 0.2 ml/min using a micro infusion pump (Medexinc, Duluth, GA, USA). A standard blood pressure cuff was placed around the upper arm and the LVDT (linear variable differential transformer) (MHR 025, Lucas Control System, Hampton, VA, USA) was positioned within 1 cm of the end of the infusion needle. The cuff was then inflated and deflated to check for a displacement signal indicating good LVDT positioning. Finally, the test hand and arm were covered with towels to retain heat.
Subjects remained supine with the saline infusion running for at least 20 min before baseline distention of the relaxed vein in response to a cuff inflation to 40 mmHg was determined. Then commenced the serial infusions of drugs diluted in room temperature normal saline to the appropriate concentrations for delivery at a uniform volumetric rate of 0.2 ml/min. The effects of norepinephrine alone, insulin plus norepinephrine and heparin plus norepinephrine were assessed. Norepinephrine was delivered at a rate of 0.59 nmol/min (100 ng/min) whether alone or in conjunction with other test drugs. This dose of norepinephrine has been shown to produce venoconstriction in all subjects. 17 Norepinephrine alone was infused for at least 10 min before any combined heparin and norepinephrine or insulin and norepinephrine infusion. The infusions of the drug combinations also were delivered for a minimum of 10 min. At least 15 min of washout with normal saline were allowed between the insulin and heparin infusions. Vessels always returned to baseline conditions with saline washout.
Insulin at a dose of 1.84 pmol/min (256 U/min) with norepinephrine, or heparin at doses of 1.85, 18.5, 185 nmol/min and 1.85 mol/min (0.005 to 5.0 U/min), also with norepinephrine, were infused. The additivity of the insulin and heparin effects were checked by infusing a combination of heparin 1.85 mol/min, insulin 1.84 pmol/min and norepinephrine. The importance of guanylate cyclase in the heparin-induced vasorelaxation was tested with combined heparin 1.85 mol/min, methylene blue 335 pmol/min (0.125 g/min) and norepinephrine in four subjects, and combined heparin 18.5 nmol/min, methylene blue 335 pmol/min and norepinephrine in three subjects. To check for heparin dilation of vessels not constricted by norepinephrine, heparin 1.85 mol/min alone was infused in a relaxed vein not yet exposed to norepinephrine in three subjects.
Time did not allow all test doses to be infused in every subject. All 13 subjects were given norepinephrine alone. Most subjects (11) received the highest dose of heparin (1.85 mol/min) combined with norepinephrine. Subjects were assigned to receive the other test combinations, including the lower heparin doses, the day before the experiment. Combinations of heparin 185 nmol/min and norepinephrine were given to five subjects, heparin 18.5 nmol/min with norepinephrine to seven subjects and heparin 1.85 nmol/min with norepinephrine to four subjects. Insulin plus norepinephrine was given to 11 subjects, and insulin plus heparin plus norepinephrine to four subjects. Methylene blue plus heparin and norepinephrine was given to seven subjects as detailed above.
An LVDT was used to measure vessel size. Similar methods have been used by other investigators to study vascular reactivity. 19, 23, 24 In this non-invasive technique, the lightweight movable core of a miniature transformer rests on the skin surface immediately over a superficial vein. The LVDT produces a voltage proportional to linear displacement of its core. The signal was monitored on a computer screen, and data were stored when the signal stabilized after an experimental manipulation. The changes in venous diameter of a cephalic or dorsal hand vein in response to a 40 mm Hg distending pressure were recorded. LVDT readings were taken before and after at least 2 min of cuff inflation. The lowest LVDT reading seen with the brachial cuff deflated was considered to represent the minimum vessel size. Differences in LVDT values from that zero point are referred to as vein size, given in mm. This is close Vascular Medicine 1998; 3: 95-100 to, but not necessarily equal to, internal venous diameter. Percentage reversal of norepinephrine constriction is defined as:
(size with dilator − size with norepinephrine alone) (size with saline − size with norepinephrine alone) × 100.
Percentage reversal of constriction normalizes for vein size and for sensitivity to norepinephrine. It is insensitive to errors in the LVDT 'zero' reading. It is therefore a better measure of dilatory effect than vein size itself.
Repeated measures ANOVA with contrasts were used to test for overall treatment effects. Vein size and percentage reversal of norepinephrine-induced constriction were analysed pairwise using Student's t-tests with Bonferroni correction as appropriate. The vein sizes and percentage reduction of constriction with heparin and insulin were compared using Student's paired t-test and the correlation between these measures was computed using orthogonal regression to account for random error in both insulin and heparin values. Repeated measures ANOVA were used to test the effect of methylene blue on heparin-induced venodilation.
Results
All subjects were studied without complications. With the cuff inflated to 40 mmHg and only normal saline running, the mean vessel size was 0.52 Ϯ 0.05 mm, with a range from 0.33 mm to 0.85 mm. Heparin infused into relaxed veins did not change the vessel size from that with saline alone. With only norepinephrine 0.59 nmol/min (NE) in the infusate, the vessel size was 0.10 Ϯ 0.02 mm, with a range of 0-0.21 mm. When the maximum dose of heparin (1.85 mol/min) mixed with norepinephrine was infused, the vessel size was 0.30 Ϯ 0.07 mm with a range of 0.11-0.80 mm (47 Ϯ 10% reversal of norepinephrine constriction; range 0-109%). When insulin 1.84 pmol/min was infused concurrently with norepinephrine, the vein size increased to 0.28 Ϯ 0.04 mm, with a range of 0.13-0.53 mm (48 Ϯ 8% reversal of norepinephrine constriction; range 19-96%). Figure 1 shows the percentage reversal of constriction (mean Ϯ SE) by heparin and insulin. Percentage reversal of constriction increased with increasing heparin doses. Veins were significantly more dilated with heparin 18.5 nmol/min and heparin 1.85 mol/min than with NE alone by repeated measures ANOVA (F = 8.5, n = 6, p = 0.007), and the vein size with heparin 1.85 mol/min was greater than that with heparin 1.85 nmol/min (F = 11.1, p Ͻ 0.03). Individual tests of the effects of the different heparin doses are reported in detail in Table 1 . Briefly, constriction was reversed significantly with the highest heparin dose, either on a per experiment or per comparison basis. On a per comparison basis only, significant reversal of constriction was seen with both heparin 18.5 nmol/min and 1.85 nmol/min. Again, on a per comparison basis only, vein size was greater with heparin 1.85 nmol/min, 18.5 nmol/min and 1.85 mol/min than with NE. Reversal of constriction with insulin was highly significant (t = 6.33, p Ͻ 0.001) and vein size with insulin was significantly greater than that with NE (t = 6.01, p Ͻ 0.001).
Neither percentage reversal of constriction nor maximum vessel size with the highest dose of heparin (H4) differed from that with insulin (n = 10; 95% confidence intervals: (size with insulin − size with H4) = 0.01 Ϯ 0.07 mm; (% reversal with insulin − % reversal with H4) = 4 Ϯ 12%). In fact, the vein sizes with H4 and insulin (I) were highly correlated (n = 10, r = 0.8, p Ͻ 0.01), with an orthogonal regression slope of 1.05 Ϯ 0.5 and an intercept of −0.04 Ϯ 1.7 mm. The percentage reversals with H4 and insulin also were highly correlated (r = 0.7, p Ͻ 0.03) ( (Figure 3 ). Vessel size decreased from 0.43 Ϯ 0.08 mm with heparin and norepinephrine to 0.33 Ϯ 0.06 mm with heparin, methylene blue and norepinephrine (p Ͻ 0.007, n = 7). This represents a significant decrease (p Ͻ 0.005) in heparininduced venorelaxation from a mean of 60% reversal of norepinephrine-induced constriction to a mean of 37% reversal. In one subject methylene blue had no effect. 
Discussion
Heparin is vasoactive in human hand veins, attenuating norepinephrine-induced venoconstriction. A classic doseresponse effect over four logarithms of doses from 1.85 nmol/min to 1.85 mol/min was observed. Significant attenuation of norepinephrine-induced constriction occurred at a heparin infusion rate of 18.5 nmol/min, lower than doses used clinically. The plateau of maximum attenuation began at an infusion rate between 185 nmol/min and 1.85 mol/min. Because the heparin doses used spanned pharmacologic and physiologic ranges as described below, Figure 3 Percentage reversals (mean Ϯ SE) of norepinephrine (NE)-induced venoconstriction. NE 0.59 nmol/min (100 ng/min) was used. Significant reversal of constriction was seen when heparin 1.85 mol/min (5 U/min) was added to NE; insulin 1.84 pmol (256 U/min ) was added to NE; or heparin plus insulin were added to NE (n = 4). Addition of insulin to heparin resulted in no further venodilation relative to that seen with either drug alone. Methylene blue 335 pmol/min (0.125 g/min) blunted the venorelaxation seen with heparin plus NE (p Ͻ 0.005), but significant reversal of constriction remained (n = 7). Vascular Medicine 1998; 3: 95-100 it is likely that heparin modulates vascular tone at both physiologic and pharmacologic concentrations.
If it is assumed that the heparin infusate (9.25 nmol to 9.25 mol/ml at 0.2 ml/min) was diluted by blood to give an average venous flow of 5 ml/min, then the heparin concentration-response curve spanned the range of 0.0037 to 37 mol/ml (0.001 to 1 U/ml). Total extractable heparin has been detected in normal human plasma at concentrations of 0.1-0.4 U/ml, 14, 25, 26 but most of this appears to be inactivated by tight binding to plasma proteins. If even 1% of the extractable native heparin is biologically available, it has been shown that it could relax constricted veins. Therapeutic serum concentrations of heparin with anticoagulant activity have been estimated to be 0.2-0.4 U/ml by the protamine titration method, or 0.3-0.7 U/ml by the anti-Xa method. 27 At most, one-third of the total exogenous heparin concentration has anticoagulant properties, 27 putting therapeutic total heparin concentrations in the approximate range of 0.6-2.8 U/ml.
Insulin effects consistent with maximal insulin-induced venorelaxation seen in other studies were observed. 17, 19, 25 Grover et al constructed dose-response curves for insulin in veins constricted with norepinephrine 0.59 nmol/min. Insulin at 32 U/min caused maximal reversal of norepinephrine-induced venoconstriction. 17 Because a maximal effect is important in studies using combinations to infer a shared mechanism of action, an insulin dose eight times higher was used. This is well within the range of doses where insulin relaxes constricted vessels; Feldman et al 19 used insulin doses 1000-fold higher in 5% dextrose to counteract phenylephrine. A similar degree of insulininduced reversal of norepinephrine constriction was observed to that reported by Feldman et al. 19 No greater relaxation was attained when insulin was added to heparin although reversible venoconstriction usually remained after maximal dilation by either substance. Individuals reacted similarly to the vasodilatory actions of the two drugs, as seen in the correlation (Figure 2 ). Those who dilated poorly with heparin also dilated poorly with insulin. In other words, individuals were similarly sensitive to the venodilatory effects of insulin and heparin.
Venodilation mediated by heparin appears to depend in part on the nitric oxide-cGMP pathway. First, as discussed above, veins that were relaxed to the maximum degree possible with heparin were not further relaxed by the addition of insulin at doses for peak relaxation (Figure 3) , and insulin is known to stimulate nitric oxide release from venous endothelium. Secondly, the venodilatory effects of heparin and insulin were proportional within and across individuals (Figure 2) , implying a common mechanism. Thirdly, methylene blue blunted the heparin-induced venodilation ( Figure 3) .
Methylene blue 335 pmol/min blunted but did not eliminate the venorelaxation caused by either of the two doses of heparin tested. This raises the possibility that heparininduced venorelaxation is not solely mediated through nitric oxide or cGMP. 9 In previous work, 17 methylene blue doses of 335 pmol/min to 335 mol/min abolished insulinmediated venodilation. In this study, methylene blue doses were kept low because the higher doses had caused forearm pain and severe headaches. Although adequacy of methylene blue dosing may have been an issue, only partial blunting of the heparin-induced relaxation was seen, even when the heparin dose was reduced by a factor of 10. Methylene blue may be insufficiently specific for guanylate cyclase 28 or for the nitric oxide -cGMP cascade in general. 29, 30 An interaction of heparin and methylene blue, 31 which could deactivate methylene blue, could also have occurred. Possibly, though improbably, heparin causes venorelaxation to a similar degree but by a different mechanism than insulin. Nevertheless, it seems likely that much of the venorelaxation induced by heparin occurs by pathways dependent on nitric oxide generation. The authors do not have data using a specific NO synthase inhibitor.
Evidence is presented that heparin may enhance nitric oxide release in in situ veins exposed to norepinephrine. In contrast, heparin 5 U/ml has been shown in vitro to lower endothelial cell production of nitric oxide after 4 h of incubation in a static medium. 32 In that study, equimolar dextran sulfate was more potent than heparin in suppressing nitric oxide production, and heparin 0.5 U/ml had no measurable effect on nitric oxide levels. The polyanionic structures of heparin and dextrose were considered to be the reason for the effect. In the experiments, it was estimated that the maximum heparin concentration would be 1 U/ml. The maximum contact time for any infusion rate of heparin was 20 min in a vein exposed to flowing blood, where the baseline supply of polyanions is high. Further, norepinephrine was present throughout the heparin exposure. The difference between these results and those from the cell culture work could result from different baseline conditions, lower concentrations of heparin, shorter duration of exposure, or other in vivo to in vitro differences.
The heparin effects have been measured in veins but qualitatively similar effects would be expected in arteries. In fact, arteries are more sensitive than veins to dilation caused by stimulation of nitric oxide release. 33 Similar patterns of endothelial dysfunction have been seen in in vivo veins 34 and in systemic and coronary arteries, 35, 36 and the authors would expect their findings to be applicable to the arterial vasculature as well.
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